HistoIndex, A*STAR Sign MoU on Fibrosis Drug Candidate Testing
Image
Singapore – October 18, 2026 -- HistoIndex and Singapore's Agency for Science, Technology and Research (A*STAR) have signed a Memorandum of Understanding to jointly run preclinical evaluation and characterization of therapeutic candidates for fibrotic diseases, including cancer-associated fibrosis.
A*STAR pipeline candidates will be measured with HistoIndex's AI-based tissue analysis
The agreement pairs A*STAR's therapeutic development capabilities with HistoIndex's proprietary imaging technology and fully quantitative, AI-powered tissue analysis. HistoIndex's platform will provide objective, sensitive and accurate measures of fibrosis and treatment response across A*STAR's pipeline. Researchers are expected to use the data to decide which candidates to advance.